Navigation Links
Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies

or in combination were administered at different time points. Treatment with the combination regimen reduced the growth of small tumors by 80% to 82% and of well-established tumors by 92% to 94%. The anti-tumor effect of the combination regimen was significantly superior to that of the individual treatments (P < 0.01). Yet the combination therapy was no more toxic to the mice than was docetaxel alone as judged by physical signs and body weight changes.

Tumor microvessel density, which is correlated with tumor growth rates, was further reduced in tumors treated with the combination regimen compared with tumors from single agent-treated animals. In addition, serum PSA levels in combination-treated mice registered a significantly greater decrease (P < 0.05) in one of the tumor models compared to the decrease seen in either the docetaxel-treated or 2aG4-treated animals.

Bavituximab is a targeted monoclonal antibody that binds to a phospholipid called phosphatidylserine, which is located on the inside of normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, thus creating a specific target for anti-cancer treatments. Once bound to the tumor blood vessels, bavituximab alerts the body's immune system to attack the tumor's blood supply, stopping the flow of oxygen and nutrients to the tumor cells and resulting in tumor cell death. As an anti-cancer immunotherapeutic, bavituximab may have broad potential in a wide variety of solid cancers. It is currently in Phase Ia cancer safety trials as a monotherapy and in a Phase Ib trial in combination with docetaxel and other chemotherapy agents in patients with advanced solid cancers, including prostate, breast and lung cancer. Interim data indicate that more than half of the cancer patients in this study who have completed treatment to date were assessed as demonstrating stable disease or an objective response.

Prostate cancer is the most commonly diagnosed c
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:9/22/2014)... ALISO VIEJO, Calif. , Sept. 22, 2014 /PRNewswire/ ... today announced that it is offering to sell $200 ... offering.  J.P. Morgan, Deutsche Bank Securities and BofA Merrill ... offering.  Avanir intends to grant the underwriters a 30-day option ... of the shares to be sold in the offering ...
(Date:9/22/2014)... 22, 2014 The western European automated ... is largely a replacement market with fewer new ... acquisitions and partnerships are redefining competitive landscape in ... service provides details about revenue forecasts, unit shipments, ... across the country. The changing landscape makes it ...
(Date:9/22/2014)... , September 22, 2014 ... announced the addition of the  "Global Remotes ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Remotes/remote ... wirelessly operate electronic gadgets such as smart ... from a short line-of-sight distance. Remote controls ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3Global Remotes Market 2014-2018 2Global Remotes Market 2014-2018 3
... 9 Avinger, Inc., a medical device company ... combat peripheral artery disease, announces the enrollment of ... OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial. ... study intended to evaluate the Wildcat Catheter,s ability ...
... (Nasdaq: PCYC ), a biopharmaceutical company focused ... the treatment of cancer and mediated diseases, today announced ... fiscal quarter and fiscal year ended June 30, 2010 ... 2010.  The company will conduct a conference call and ...
Cached Medicine Technology:First Patient Enrolled in 'CONNECT' Clinical Trial 2Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference 2
(Date:9/22/2014)... Los Angeles, CA (PRWEB) September 22, 2014 ... the life insurance industry is now easier using the ... adults who are trying to local universal life insurance ... , The adult coverage plans that are easily viewed ... companies that underwrite specific lengths of coverage. The plan ...
(Date:9/22/2014)... Teens and young adults at risk for sexually transmitted ... risky sexual behaviors, according to new recommendations from the ... 20 million new sexually transmitted infections such as gonorrhea ... involve people between 15 and 24 years old, according ... published Sept. 22 in Annals of Internal Medicine ...
(Date:9/22/2014)... All sexually active women should be screened for ... chlamydia and gonorrhea, according to new recommendations from ... The task force noted this recommendation includes older ... and pregnant women. Most women with chlamydia ... result, many infections go undetected. If left untreated, ...
(Date:9/22/2014)... ARBOR, Mich. A surprising new study pulls back ... in health care: differences in payment and income between ... who don,t. , Contrary to perception, the research ... to favor surgeons and other procedure-performing doctors. , The ... simple difference in pay per minute explains why doctors ...
(Date:9/22/2014)... New York, New York (PRWEB) September 22, 2014 ... ) filed against Boston Scientific Corp. continue to ... underway in U.S. District Court, Southern District of ... court documents, a new Docket Control Order was ... addresses a number of matters pertaining to the ...
Breaking Medicine News(10 mins):Health News:Universal Life Insurance Prices for Adults Added to National Insurer Portal Online 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 4
... Nyer Medical Group, Inc., (Nasdaq: NYER ) announced ... notifying it of its failure to maintain a minimum closing bid ... for the prior 30 consecutive business days as required by Nasdaq ... the Company has until March 15, 2010, to regain compliance with ...
... ANGELES, Sept. 21 Former House Majority leader Tom Delay, who injured ... all on the line when he and dance partner Cheryl Burke, a ... network. , , Last week, Delay was ... in Marina del Rey, Calif. headed by Dr. Robert S. Bray, Jr., ...
... , RADNOR, Pa., Sept. 21 ... today announced that its TripProtector(SM)( )insurance plans are now ... to $1 million and medical assistance services that include ... 180 countries. Most trip protection plans on the market ...
... dementia, study found , MONDAY, Sept. 21 (HealthDay News) ... people with mild memory problems will soon develop Alzheimer,s ... older people with mild cognitive impairment, and 76 others ... money management test at the start of the study ...
... Montana city, incidents fell but rose again when restrictions were ... ban smoking in bars, restaurants and other public places witness ... , The research -- which incorporated data from a total ... found at least a 17 percent reduction in heart attacks ...
... , EMERYVILLE, Calif., Sept. 21 Bionovo, Inc. (Nasdaq: ... the company received a letter from NASDAQ stating that, for the ... stock has closed below the minimum $1.00 per share requirement for ... that the company has been provided a period of 180 calendar ...
Cached Medicine News:Health News:Nyer Medical Group, Inc., Nasdaq Notification Letter 2Health News:Injured Tom Delay to Put Foot to Test in Debut of Dancing With the Stars Premiere Tonight on ABC 2Health News:HTH Worldwide Introduces Trip Protection Insurance With Major Medical Benefits 2Health News:Mishandling Money May Foreshadow Alzheimer's 2Health News:Smoking Bans Bring a Drop in Heart Attacks 2Health News:Smoking Bans Bring a Drop in Heart Attacks 3Health News:Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency 2Health News:Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency 3
Hardy pituitary spoon, bayonet, malleable....
... Spinal Implant system. Material that has a ... bone. The result is an implant that ... support, while optimizing the fusion environment through ... anatomic design with 5 and 10 degrees ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
A new generation of cage suitable for both PLIF and ALIF indications....
Medicine Products: